Knight Therapeutics Statistics

Total Valuation

Knight Therapeutics has a market cap or net worth of CAD 523.17 million. The enterprise value is 405.29 million.

Market Cap	523.17M
Enterprise Value	405.29M

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Knight Therapeutics has 100.80 million shares outstanding. The number of shares has decreased by -7.23% in one year.

Current Share Class	n/a
Shares Outstanding	100.80M
Shares Change (YoY)	-7.23%
Shares Change (QoQ)	-0.19%
Owned by Insiders (%)	22.43%
Owned by Institutions (%)	23.81%
Float	65.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	152.65
PS Ratio	1.52
PB Ratio	0.68
P/TBV Ratio	1.28
P/FCF Ratio	10.38
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.76, with an EV/FCF ratio of 8.04.

EV / Earnings	-13.19
EV / Sales	1.16
EV / EBITDA	6.76
EV / EBIT	39.45
EV / FCF	8.04

Financial Position

The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.08.

Current Ratio	3.36
Quick Ratio	2.33
Debt / Equity	0.08
Debt / EBITDA	0.97
Debt / FCF	1.16
Interest Coverage	0.95

Financial Efficiency

Return on equity (ROE) is -3.87% and return on invested capital (ROIC) is 0.74%.

Return on Equity (ROE)	-3.87%
Return on Assets (ROA)	0.65%
Return on Capital (ROIC)	0.74%
Revenue Per Employee	480,879
Profits Per Employee	-42,385
Employee Count	725
Asset Turnover	0.35
Inventory Turnover	1.59

Taxes

Income Tax	-6.74M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +0.78% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+0.78%
50-Day Moving Average	5.39
200-Day Moving Average	5.64
Relative Strength Index (RSI)	42.52
Average Volume (20 Days)	178,022

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Knight Therapeutics had revenue of CAD 348.64 million and -30.73 million in losses. Loss per share was -0.30.

Revenue	348.64M
Gross Profit	168.27M
Operating Income	10.27M
Pretax Income	-31.98M
Net Income	-30.73M
EBITDA	57.36M
EBIT	10.27M
Loss Per Share	-0.30

Full Income Statement

Balance Sheet

The company has 172.32 million in cash and 58.22 million in debt, giving a net cash position of 117.88 million or 1.17 per share.

Cash & Cash Equivalents	172.32M
Total Debt	58.22M
Net Cash	117.88M
Net Cash Per Share	1.17
Equity (Book Value)	773.91M
Book Value Per Share	7.66
Working Capital	279.41M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 52.75 million and capital expenditures -2.35 million, giving a free cash flow of 50.40 million.

Operating Cash Flow	52.75M
Capital Expenditures	-2.35M
Free Cash Flow	50.40M
FCF Per Share	0.50

Full Cash Flow Statement

Margins

Gross margin is 48.26%, with operating and profit margins of 2.95% and -8.81%.

Gross Margin	48.26%
Operating Margin	2.95%
Pretax Margin	-9.17%
Profit Margin	-8.81%
EBITDA Margin	16.45%
EBIT Margin	2.95%
FCF Margin	14.46%

Dividends & Yields

Knight Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	7.23%
Shareholder Yield	7.23%
Earnings Yield	-5.85%
FCF Yield	9.63%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Knight Therapeutics has an Altman Z-Score of 2.74 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.74
Piotroski F-Score	6